Pfizer (NYSE:PFE) Price Target Raised to $28.00

Pfizer (NYSE:PFE) had its price target raised by analysts at Royal Bank Of Canada from $25.00 to $28.00 in a report released on Wednesday, Benzinga reports. The brokerage currently has a “sector perform” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada‘s target price points to a potential downside of 8.27% from the company’s previous close.

PFE has been the topic of a number of other reports. Bank of America cut their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. JPMorgan Chase & Co. boosted their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a report on Friday, October 9th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research report on Tuesday, October 13th. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday, October 10th. Finally, Weiss Ratings raised shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 31st. Five analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $28.82.

Pfizer Stock Up 1.7%

Shares of NYSE PFE traded up $0.53 during mid-day trading on Wednesday, hitting $30.52. The company had a trading volume of 19,826,121 shares, compared to its average volume of 39,685,324. The company has a market capitalization of $173.98 billion, a PE ratio of 40.13, a price-to-earnings-growth ratio of 2.08 and a beta of 0.31. The business’s 50-day simple moving average is $28.64 and its 200 day simple moving average is $26.84. Pfizer has a 1-year low of $23.62 and a 1-year high of $31.06. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.74 by $0.13. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The firm had revenue of $16.58 billion during the quarter, compared to analysts’ expectations of $15.85 billion. During the same period in the previous year, the firm posted $0.87 EPS. Pfizer’s revenue for the quarter was down .4% on a year-over-year basis. On average, analysts predict that Pfizer will post 2.94 earnings per share for the current year.

Hedge Funds Weigh In On Pfizer

Hedge funds and other institutional investors have recently bought and sold shares of the company. Retirement Wealth Solutions LLC increased its stake in Pfizer by 144.6% in the 3rd quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 509 shares during the period. Keb Asset Management LLC purchased a new stake in shares of Pfizer in the second quarter valued at about $26,000. Field & Main Bank acquired a new position in shares of Pfizer during the second quarter worth about $27,000. Bullseye Investment Management LLC acquired a new position in shares of Pfizer during the second quarter worth about $28,000. Finally, Timbuktu Capital Management LLC purchased a new position in Pfizer during the second quarter worth about $29,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer raised its 2026 revenue outlook to $62 billion–$64 billion and adjusted EPS guidance to $2.95–$3.05, following third-quarter results that topped analyst estimates. Pfizer Q3 earnings highlights
• Positive Sentiment: Growth beyond COVID is helping support the outlook: launched and acquired products grew 32% operationally in Q3, while non-COVID products overall grew 7%. Eliquis and oncology medicines were among the growth drivers. Pfizer: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Investors also have potential longer-term upside to watch in Pfizer’s renewed obesity-drug push, which CEO Albert Bourla says could draw on the company’s experience building successful medicines. The opportunity is not yet established commercial growth. Pfizer CEO Bourla on obesity market
• Neutral Sentiment: Pfizer appointed company veteran Cecile Guegan as permanent CFO. The appointment provides leadership continuity, but no immediate financial impact was reported. Pfizer appoints Cecile Guegan as CFO
• Negative Sentiment: Q3 revenue was essentially flat year over year, as falling COVID vaccine and treatment sales—including declines in Comirnaty and Paxlovid—offset growth elsewhere. This underscores Pfizer’s ongoing need to replace pandemic-era revenue. Pfizer Q3 revenue and product growth

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.